Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05203380 · ClinicalTrials.gov registry record
Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
A clinical trial, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- 45
- Enrollment target
NCT05203380 is a clinical trial that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 45 participants.
The verdict
NCT05203380 has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- 45 participants
- Enrollment target
Study Summary
Primary Objective: Part A * To quantify deficits in cognitive functioning in adolescents with moderate-to-severe AD, using the Conners' Continuous Performance Test 3rd Edition (CPT-3) d' T-score * To determine the entry criterion (CPT-3 d' score) for Part B Primary Objective: Part B * To measure changes in cognitive functioning in adolescents with moderate-to-severe AD treated with dupilumab Secondary Objectives * To evaluate the relationship of cognitive and sensory functioning with severity of AD in adolescent AD patients * To evaluate the relationship between changes in AD severity and changes in cognitive and sensory functioning scores following treatment with dupilumab (Part B only).
Interventions
- DRUG dupilumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2022-01-27 |
| Est. Completion | 2023-03-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05203380
The ClinicalTrials.gov registry entry for NCT05203380 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dupilumab is the first listed.
NCT05203380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05203380 about?
NCT05203380 is a clinical study titled "Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis". Primary Objective: Part A * To quantify deficits in cognitive functioning in adolescents with moderate-to-severe AD, using the Conners' Continuous Performance Test 3rd Edition (CPT-3) d' T-score * To determine the entry criterion (CPT-3 d' score) for Part B Primary Objective: Part B * To measure ...
What is the current status of trial NCT05203380?
This trial is currently completed. The enrollment target is 45 participants. The study started on 2022-01-27. Estimated completion is 2023-03-10.
What interventions are being tested in trial NCT05203380?
The interventions under investigation include: dupilumab (DRUG).
Who is sponsoring clinical trial NCT05203380?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.